Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

5274 ARTÍCULOS , VIENDO DEL 1066 AL 1080

The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson's disease

Brakedal B, Dölle C, Riemer F, Ma Y, Nido GS, Skeie GO, Craven AR, Schwarzlmüller T, Brekke N, Diab J, Sverkeli L, Skjeie V, Varhaug K, Tysnes OB, Peng S, Haugarvoll K, Ziegler M, Grüner R, Eidelberg D, Tzoulis C.

Cell Metab. 2022 Mar 1;34(3):396-407.e6. doi: 10.1016/j.cmet.2022.02.001.

Hydrogen Sulfide (H(2)S) Signaling as a Protective Mechanism against Endogenous and Exogenous Neurotoxicants

Aschner M, Skalny AV, Ke T, da Rocha JB, Paoliello MM, Santamaria A, Bornhorst J, Rongzhu L, Svistunov AA, Djordevic AB, Tinkov AA.

Curr Neuropharmacol. 2022;20(10):1908-1924. doi: 10.2174/1570159X20666220302101854.

Effect of galvanic vestibular stimulation on axial symptoms in Parkinson's disease

Kataoka H, Okada Y, Kiriyama T, Kita Y, Nakamura J, Shomoto K, Sugie K.

J Cent Nerv Syst Dis. 2022 Feb 24;14:11795735221081599. doi: 10.1177/11795735221081599. eCollection 2022.

How Loading Dose Strategies for Depot Paliperidone Can Go Wrong

Preskorn SH.

J Psychiatr Pract. 2022 Mar 3;28(2):130-137. doi: 10.1097/PRA.0000000000000615.

The Attention Network Test in Parkinson and Lewy Body Disease: A Systematic Review

Yang J, Pourzinal D, Rheinberger T, Copland DA, McMahon KL, Byrne GJ, Dissanayaka NN.

Cogn Behav Neurol. 2022 Mar 3;35(1):1-13. doi: 10.1097/WNN.0000000000000292.

The pathophysiology of Parkinson's disease tremor

Dirkx MF, Bologna M.

J Neurol Sci. 2022 Apr 15;435:120196. doi: 10.1016/j.jns.2022.120196. Epub 2022 Feb 19.

A Review on the Neuroprotective Effect of Berberine against Chemotherapy- induced Cognitive Impairment

Sahu K, Singh S, Devi B, Singh C, Singh A.

Curr Drug Targets. 2022;23(9):913-923. doi: 10.2174/1389450123666220303094752.

Evaluating the impact of adjunctive istradefylline on the cumulative dose of levodopa-containing medications in Parkinson's disease: study protocol for the ISTRA ADJUST PD randomized, controlled study

Hatano T, Kano O, Sengoku R, Yoritaka A, Suzuki K, Nishikawa N, Mukai Y, Nomura K, Yoshida N, Seki M, Matsukawa MK, Terashi H, Kimura K, Tashiro J, Hirano S, Murakami H, Joki H, Uchiyama T, Shimura H, Ogaki K, Fukae J, Tsuboi Y, Takahashi K, Yamamoto T, Yanagisawa N, Nagayama H.

BMC Neurol. 2022 Mar 3;22(1):71. doi: 10.1186/s12883-022-02600-w.

Volitional Control of Brain Motor Activity and Its Therapeutic Potential

Girges C, Vijiaratnam N, Zrinzo L, Ekanayake J, Foltynie T.

Neuromodulation. 2022 Dec;25(8):1187-1196. doi: 10.1016/j.neurom.2022.01.007. Epub 2022 Feb 28.

Similarities, differences and overlaps between frailty and Parkinson's disease

Ebina J, Ebihara S, Kano O.

Geriatr Gerontol Int. 2022 Apr;22(4):259-270. doi: 10.1111/ggi.14362. Epub 2022 Mar 3.

Protective effects of functional foods against Parkinson's disease: A narrative review on pharmacology, phytochemistry, and molecular mechanisms

Iranshahy M, Javadi B, Sahebkar A.

Phytother Res. 2022 May;36(5):1952-1989. doi: 10.1002/ptr.7425. Epub 2022 Mar 4.

Managing freezing of gait in Parkinson's disease: a systematic review and network meta-analysis

Kwok JYY, Smith R, Chan LML, Lam LCC, Fong DYT, Choi EPH, Lok KYW, Lee JJ, Auyeung M, Bloem BR.

J Neurol. 2022 Jun;269(6):3310-3324. doi: 10.1007/s00415-022-11031-z. Epub 2022 Mar 4.

Effects of oligomer toxicity, fibril toxicity and fibril spreading in synucleinopathies

Cascella R, Bigi A, Cremades N, Cecchi C.

Cell Mol Life Sci. 2022 Mar 4;79(3):174. doi: 10.1007/s00018-022-04166-9.

Brain-gut-microbiota axis in Parkinson's disease: A historical review and future perspective

Dong S, Sun M, He C, Cheng H.

Brain Res Bull. 2022 Jun 1;183:84-93. doi: 10.1016/j.brainresbull.2022.02.015. Epub 2022 Mar 1.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias